Maria Ignez Braghiroli

Maria Ignez Braghiroli

Auto-generated profile, based on publicly available information

Maria Ignez Braghiroli

Instituto do Cancer do Estado de São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MFMichael B. Foote
Michael B. Foote
HWHenry Walch
Henry Walch
WCWalid Chatila
Walid Chatila
EVEfsevia Vakiani
Efsevia Vakiani
CCChris Chandler
Chris Chandler
ACAndrea Cercek
Andrea Cercek
PURPOSE: Appendiceal adenocarcinomas (ACs) are rare, histologically diverse malignancies treated as colorectal cancers despite having distinct biology and clinical behavior. To guide clinical decision making, we defined molecular subtypes of AC associated with patient survival, metastatic burden, and chemotherapy response. PATIENTS AND METHODS: A comprehensive molecular analysis was performed in patients with AC to define molecular subtypes. Associations between molecular subtype and overall survival, intraoperative peritoneal cancer index, and first-line chemotherapy response were assessed adjusting for histopathologic and clinical variables using multivariable Cox proportional hazards, linear regression, and logistic regression models. RESULTS: We defined distinct molecular lineages of mucinous appendiceal adenocarcinoma (MAAP) from co-occurring mutations in GNAS, RAS, and TP53. Of 164 MAAP tumors, 24 were RAS-mutant (mut) predominant ( RAS-mut/ GNAS-wild-type [wt]/ TP53-wt) with significantly decreased mutations and chromosomal alterations compared with tumors with GNAS mutations (GNAS-mut predominant) or TP53 mutations (TP53-mut predominant). No patient with RAS-mut predominant subtype metastatic MAAP died of cancer, and overall survival in this subgroup was significantly improved compared with patients with GNAS-mut ( P = .05) and TP53-mut ( P = .004) predominant subtypes. TP53-mut predominant subtypes were highly aneuploid; increased tumor aneuploidy was independently ( P = .001) associated with poor prognosis. The findings retained significance in patients with any metastatic AC. RAS-mut predominant metastases exhibited reduced peritoneal tumor bulk ( P = .04) and stromal invasion ( P < .001) compared with GNAS-mut or TP53-mut predominant tumors, respectively. Patients with RAS-mut predominant MAAP responded more to first-line chemotherapy (50%) compared with patients with GNAS-mut predominant tumors (6%, P = .03). CONCLUSION: AC molecular patterns identify distinct molecular subtypes: a clinically indolent RAS-mut/GNAS-wt/TP53-wt subtype; a chemotherapy-resistant GNAS-mut predominant subtype; and an aggressive, highly aneuploid TP53-mut predominant subtype. Each subtype exhibits conserved clinical behavior irrespective of histopathology.

1 January 2020 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
PDF file
ACAline Lopes Chagas
Aline Lopes Chagas
AMAngelo Alves de Mattos
Angelo Alves de Mattos
FCFlair Jose Carrilho
Flair Jose Carrilho
PBPaulo Lisboa Bittencourt
Paulo Lisboa Bittencourt
DVDenise Cerqueira Paranaguá Vezozzo
Denise Cerqueira Paranaguá Vezozzo
TCThaisa de Fátima Almeida Costa
Thaisa de Fátima Almeida Costa
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first recommendations about the management of HCC. Since then, new data have emerged in the literature, prompting the governing board of SBH to sponsor a single-topic meeting in August 2018 in São Paulo. All the invited experts were asked to make a systematic review of the literature reviewing the management of HCC in subjects with cirrhosis. After the meeting, all panelists gathered together for the discussion of the topics and the elaboration of updated recommendations. The text was subsequently submitted for suggestions and approval of all members of the Brazilian Society of Hepatology through its homepage. The present manuscript is the final version of the reviewed manuscript containing the recommendations of SBH.

1 January 2021 in Clinics
Verified
Journal Article
Open access
NGNader Marta Guilherme
Nader Marta Guilherme
LFLeonardo Da Fonseca
Leonardo Da Fonseca
MBMaria Ignez Braghiroli
Maria Ignez Braghiroli
FMFernando Moura
Fernando Moura
PHPaulo M. Hoff
Paulo M. Hoff
JSJorge Sabbaga
Jorge Sabbaga
To evaluate the efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC).We analyzed data from a cohort of patients with advanced HCC treated using systemic treatment according to the local institutional protocol. ...

1 January 2017 in Clinics
Verified
Journal Article
Open access
GFGustavo S. Fernandes
Gustavo S. Fernandes
DMDaniel F. Marques
Daniel F. Marques
DGDaniel Girardi
Daniel Girardi
MBMaria Ignez F. Braghiroli
Maria Ignez F. Braghiroli
RCRenata A. Coudry
Renata A. Coudry
PHPaulo M. Hoff
Paulo M. Hoff
With the development of next-generation sequencing (NGS) technologies, DNA sequencing has been increasingly utilized in clinical practice. Our goal was to investigate the impact of genomic evaluation on treatment decisions for heavily pretreated patients with metastatic cancer. We analyzed metastatic cancer patients from a single institution whose cancers had progressed after all available standard-of-care therapies and whose tumors underwent next-generation sequencing analysis. We determined the percentage of patients who received any therapy directed by the test, and its efficacy. From July 2013 to December 2015, 185 consecutive patients were tested using a commercially available next-generation sequencing-based test, and 157 patients were eligible. Sixty-six patients (42.0%) were female, and 91 (58.0%) were male. The mean age at diagnosis was 52.2 years, and the mean number of pre-test lines of systemic treatment was 2.7. One hundred and seventy-seven patients (95.6%) had at least one identified gene alteration. Twenty-four patients (15.2%) underwent systemic treatment directed by the test result. Of these, one patient had a complete response, four (16.7%) had partial responses, two (8.3%) had stable disease, and 17 (70.8%) had disease progression as the best result. The median progression-free survival time with matched therapy was 1.6 months, and the median overall survival was 10 months. We identified a high prevalence of gene alterations using an next-generation sequencing test. Although some benefit was associated with the matched therapy, most of the patients had disease progression as the best response, indicating the limited biological potential and unclear clinical relevance of this practice.

1 July 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
LFLeonardo Da Fonseca
Leonardo Da Fonseca
CFCecília Souza Freire
Cecília Souza Freire
RGRodrigo Antonio Vieira Guedes
Rodrigo Antonio Vieira Guedes
MLMarcos Castro Lyra
Marcos Castro Lyra
MBMaria Ignez Freitas Melro Braguiroli
Maria Ignez Freitas Melro Braguiroli
PHPaulo Marcelo Hoff
Paulo Marcelo Hoff
PURPOSE: Immunotherapy-based combinations have shown promising survival benefits in patients with hepatocellular carcinoma (HCC) included in clinical trials. However, real-world data are needed to assess the effectiveness and safety of these therapies in diverse clinical settings and regions. PATIENTS AND METHODS: We conducted a Brazilian multicenter observational study, including 163 patients with unresectable or metastatic HCC treated with immunotherapy between August 2020 and March 2024 in 14 centers. Patient characteristics, treatment outcomes, and adverse events were analyzed. Survival outcomes were assessed using the Kaplan-Meier method, and Cox regression identified predictors of survival. RESULTS: Most patients were male (85.3%), with a median age of 72 years. Liver cirrhosis was present in 70.6%, and 77% had Barcelona Clinic Liver Cancer stage C. Immunotherapy was predominantly first-line (91.4%), with atezolizumab plus bevacizumab as the most common regimen (77.9%). The median treatment duration was 4.9 months, and the median overall survival (OS) was 14.7 months (95% CI, 11.6 to 24.5), with 12- and 24-month survival rates of 57.0% and 41.4%, respectively. Considering the patients with Child-Pugh A and performance status 0-1 (n = 116), the median OS was 20.6 months (95% CI, 12.4 to 25.8). Immune-related adverse events occurred in 19.6%, mainly thyroid disorders and skin manifestations. Adverse events related to bevacizumab included variceal (n = 6) and other bleeding events (n = 7). Albumin-bilirubin grade 2 to 3, metabolic dysfunction–associated steatotic liver disease, and esophagogastric varices were independently associated with reduced OS. CONCLUSION: In a real-world setting, immunotherapy-based treatments demonstrated effectiveness and safety profiles consistent with clinical trials, although survival was influenced by liver function, etiology, and baseline variceal status. These findings highlight the relevance of baseline liver disease characteristics in guiding immunotherapy in HCC and underscore the need for tailored management strategies.

1 January 2024 in ABCD. Arquivos Brasileiros de Cirurgia Digestiva (São Paulo)
Verified
Journal Article
Open access
PDF file
MSMarília Polo Mingueti e Silva
Marília Polo Mingueti e Silva
JSJorge Sabbaga
Jorge Sabbaga
HNHenry Luiz Najman
Henry Luiz Najman
CNCarlos David Carvalho Nascimento
Carlos David Carvalho Nascimento
RCRicardo Lemos Cotta-Pereira
Ricardo Lemos Cotta-Pereira
IAInternational Hepato-Pancreato-Biliary Association
International Hepato-Pancreato-Biliary Association
Colorectal cancer (CRC) is a common disease, with incidence in Brazil of 45,630 new cases per 100,000 inhabitants between 2023-2025. Risk factors for CRC can be evaluated between environmental and hereditary and their mode of presentation are classified as sporadic, inherited and familial. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. Sporadic disease is characterized by the absence of a family history and accounts for approximately 70% of all colorectal cancers, being more common over 50 years of age, with dietary and environmental factors implicated in its pathogenesis. The percentage of patients with a true hereditary genetic predisposition is less than 10%, and these are related to the presence or absence of colonic polyps as an important manifestation of the disease. Non-polyposis diseases are known as hereditary non-polypomatous colorectal cancer (HNPCC) or Lynch syndrome, and polyposis diseases are familial adenomatous polyposis (FAP), MUTYH-associated polyposis (MAP), and hamartomatous polyposis syndromes (e.g., Peutz-Jeghers, juvenile polyposis, phosphatase and tensin homologue - PTEN, Cowden syndrome). These diseases are linked to a high risk of developing cancer. With the development of treatments in metastatic disease and the use of targeted therapies and their biomarkers, it was possible to evaluate them within clinical studies both in the primary tumor and in the correspondence of metastases.